Company Overview
| Stock Name | Circ |
|---|---|
| Stock Code | 01763 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事各類藥物及放射源產品的研究、開發、制造及銷售；伽瑪射線輻照裝置的設計、制造及安裝；提供輻照滅菌服務以及獨立醫學檢驗實驗室服務。 |
| Listing Date | 2018-07-06 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市西城區三里河南四巷1號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.china-isotope.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 21.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 48.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 518,201,280 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 20.1 |
|---|---|
| First Day Open | HK$ 20.0 |
| First Day Change | -6.94% |
| First Day Volume | 29619000.0 |
| First Day Turnover | 599830000.0 |
Use of Proceeds
| Use of Proceeds | 1、約41.7%所得款項凈額或約671.17百萬港元預期用于投資分別位于河北省香河及四川省成都市的兩個顯像診斷及治療用放射性藥品生產及研發基地，以提升我們的生產及研發能力； 2、約4.7%所得款項凈額或約75.65百萬港元預期用于建立四間生產及分銷附屬公司，以主要于中國生產及分銷锝[99mTc]標記注射液及氟[18F]脫氧葡糖注射液； 3、約5.9%所得款項凈額或約94.96百萬港元預期用于在廣東省深圳市及安徽省桐城市建立新生產設施，以擴充尿素呼氣試驗藥盒及測試儀的產能； 4、約17.7%所得款項凈額或約284.88百萬港元預期用于投資研發多種顯像診斷及治療用放射性藥品、放射源產品的原材料、醫用放射性同位素及尿素呼氣試驗產品及相關原材料； 5、約20.0%所得款項凈額或約321.90百萬港元預期用于選擇性收購； 6、約10.0%所得款項凈額或約160.95百萬港元預期用作營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
China International Capital Corporation Hong Kong Securities Limited CE AEN894
Overall Coordinators (2)
Joint Bookrunners (3)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 北京工业发展投资管理有限公司 | 235,418,400 HKD | — | 13.63% | — | 6 months | 2019-01-06 |
| 2 | 上海医药(香港)投资有限公司 | 172,929,600 HKD | — | 10.01% | — | 6 months | 2019-01-06 |
| 3 | 通程控股有限公司 | 257,178,240 HKD | — | 14.89% | — | 6 months | 2019-01-06 |
| 4 | 中国国有企业结构调整基金股份有限公司 | 176,148,000 HKD | — | 10.20% | — | 6 months | 2019-01-06 |
Directors & Management
| Chairman | 肖亞飛 |
|---|---|
| Company Secretary | 王倉忍,關秀妍 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 中國核工業集團有限公司(73.83%);李洪波(4.76%) |
|---|
